Spotlights E-Newsletter - January 2016

January Issue Highlights

Dear ACNM Members,

Once again, we are very excited to publish yet another issue of the popular ACNM online Spotlights. This publication was begun in September of 2014 with the intent to provide easy access and immediate notification to our members of important ACNM events and areas of involvement. In addition, each month an overall educational theme is chosen, such as prostate cancer state of the art diagnostic and therapeutic management, for this issue, with many write-ups from our dedicated ACNM members. If you are interested in participating, also, please contact us.

  • This January 2016 issue also includes:
  • President Subramaniam's Report on Accomplishments of ACNM in 2015
  • Renewal of membership notification
  • A list of the 2016 ACNM webinars
  • Interesting case of the month
  • The awardees for the Lifetime Achievement, Fellowships, Best Mentors, and Best abstracts awards to be presented at the annual meeting this month in Orlando, Florida.

A brief summary paragraph will be given in this original document, then you can click on “Read more” to gain further information on the topic.

Simin Dadparvar MD, FACNM
Editor

Twyla Bartel, DO, MBA, FACNM
Associate Editor

President’s Message and Report Card … A Year in Review
Rathan Subramaniam, MD, PhD, MPH, FACNM
‘The mission in life is not just merely to survive but to thrive’….with some passion, compassion, humor and style’…. this quote from Maya Angelou aptly applies to ACNM in 2015. ACNM greatly thanks everyone for the collective efforts as we celebrate our transformative achievements in 2015. Read more.

Renew Your ACNM Membership
ACNM membership expired on December 31, 2015. Renew your membership online today for 2016 to continue taking full advantage of the comprehensive suite of benefits ACNM offers its members. We look forward to serving you in the coming year! Read more...

ACNM 2016 Annual Meeting
There's still time to make your plans to attend the 2016 ACNM Annual Meeting, January 28-31, 2016 in Orlando, FL. Register now to attend this cutting-edge event highlighting the latest advances in nuclear medicine and molecular imaging.

Highlights include:

  • Welcome Session and Oral Research Presentations
  • ACNM Annual Meeting Plenary: Challenges in Defining and Measuring Quality
  • Ensuring Safe, Quality Patient-Centered Care
  • ACNM First Annual International Session: Frontiers of Nuclear Medicine and PET
  • Useful Clinical Topics in Everyday Practice
  • Moving Forward after the ABNM/ABR Taskforce
  • Plus, don't miss the ACNM Fellow Induction & Award Ceremony Banquet

Online registration closes January 26, 2016 www.snmmi.org/mwm2016

ACNM Award Winners – Announced!
This year, the ACNM is excited this year to be inducting the very first Honorary Fellow and four ACNM Fellows. You won't want to miss the announcement of the Clinical Mentor-of-the-Year, Personal Mentor-of-the-Year or the Best Abstract Awards. Lastly, we will be recognizing our 2016 ACNM Lifetime Achievement Award winners; Henry Royal, MD, FACNM and Jack Slosky, PhD, MBA, FACNM, FASNC. We are excited about the accomplishments this past year and look forward to sharing our success with all of you during the 2016 ACNM Fellows Induction & Awards Ceremony Banquet. Read more...

ACNM Webinar Series
Twyla Bartel, DO, MBA, FACNM

  • A total of 13 webinars are planned for this year with an increase in the number of CME/SAM opportunities. Read more...
  • Register Now for the January 19, 2016 Radiation Safety Webinar. Read more...

Attention Residents!
Reminder! Don’t forget to register to attend the ACNM Fellow Induction & Award Ceremony Banquet for your chance to win one of several abstract awards this year:

  • The Ursula Mary Kocemba-Slosky, Ph.D., awards for the Best ACNM Nuclear Medicine Research Abstracts presented by NM Residents at the ACNM Annual Meeting.
            $1,000 (1st Place)
            (2) $500 awards
  • ACNM Annual Meeting Best Abstract Award (non-resident/trainees).
            (2) $500 awards

Both awards have been provided by a grant from the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF).

To win one of the above awards, you MUST be in attendance at the ACNM Fellow Induction & Award Ceremony Banquet. If you have not already registered for the 2016 ACNM Annual Meeting and SNMMI Mid-Winter Meeting, you can add your banquet ticket to your registration at the time of purchase. Click here to register for the meeting. If you have already registered for the meeting and would like to add the banquet, please complete the attached form (specific to the banquet fee and payment) and fax to: 703.708.9015.

Q&A with Dr. Neal Dunn Regarding His Experience Regarding the Role of Nuclear Medicine in Clinical Urology
Twyla Bartel, DO, MBA, FACNM
We invited Dr. Neal Dunn to talk with us about his experience in utilizing the imaging and therapeutic aspects of nuclear medicine.
Interviewer: Dr. Dunn, please give a brief history of how you decided to go into medicine and why you chose urology as your specialty?
Dr. Dunn: I fastened on medicine as a goal early in my education. I liked science in general and biology especially. If I hadn't gone into medicine, I would have gone into research or teaching. Read more...

NCCN Guidelines for Prostate Cancer Management
Chiayi Ni, MD and Gholam Reza Berenji, MD
The National Comprehensive Cancer Network (NCCN) Guidelines for management of prostate cancer were revised from Version 1.2015 to Version 1.2016. This article provides a brief overview of the recommendations for functional imaging techniques. Read more...

CT and MRI in Prostate Cancer Staging
Pareen Mehta, MD
Prostate cancer is the most common malignancy among men resulting in the second most cancer-related deaths among men. It is estimated that in the year 2015, there were over 220,000 new cases leading to over 27,000 deaths in the United States alone. While most prostate malignancies are slow-growing and of limited clinical concern, there is a subset of tumors with more aggressive features leading to significant morbidity and mortality. It is important to accurately identify these individuals and stage them such that an appropriate treatment regimen can be provided. Read more...

Basic Review of MRI Imaging of Prostate Cancer and the Future with Integrated PET/MRI
Twyla B Bartel, DO, MBA, FACNM
Introduction - MRI has already been proven to be very useful for imaging of prostate gland pathologies. MRI can be utilized for prostate cancer pretreatment diagnosis, staging, assessing resectability, surveillance, and for cases where prostate specific antigen (PSA) is elevated and biopsy is negative. It provides high contrast and spatial resolution imaging of the prostate gland soft tissues and adjacent structures. By combining PET with MRI, not only can details of the anatomic structures be viewed, but functional data is also provided. As compared to PET/CT, PET/MR offers the benefits of lower radiation exposure and higher soft tissue contrast. However, the disadvantages include a much longer imaging time and higher cost. There have been previous difficulties bringing this modality to the market, including how to perform attenuation correction, to name one area. However, the first clinical whole-body PET/MR was installed in Geneva, Switzerland, in 2010. Read more...

PET Tracers in Evaluation of Prostate Carcinoma – F-18-FDG, C-11-Choline, F18 -Choline analogues, and C11-Acetate
Manohar Kuruva, MD, Twyla Bartel, DO, MBA
Prostate cancer continues to be the most common cancer diagnosed in men. Though considered as a slow growing tumor, it has been shown to be one of the most common causes of death in men. Prostate cancer treatment consists of surgery, hormonal therapy, radiotherapy, and chemotherapy in varying degrees of combinations for better control. Imaging plays a key role in evaluation of these patients at the various stages of the disease process – staging, restaging, and recurrence detection. Read more...

F18 NaF Whole Body Bone Imaging and Tc-MDP Bone Imaging in Prostate Cancer
Yuxin Li, MD, PhD
Prostate cancer remains the most common cancer and second leading cause of cancer death in men. Bone metastasis is very common in advanced prostate cancer and is generally associated with poor prognosis. Therefore, early detection of bone metastasis in prostate cancer is critical for accurate staging, proper management, and prognosis assessment. For many decades, bone scintigraphy using technetium 99m-labeled diphosphonate compounds such as Tc-99m methylene diphosphonate (Tc-99m MDP) has been the main imaging modality to evaluate skeletal metastasis for prostate cancer.   Bone scintigraphy is highly sensitive, easy to perform, and can image the entire skeleton. Read more...     

Xofigo® Therapy in Castration-Resistant Prostate Cancer - FCCC Experience
Jian Q. (Michael) Yu, MD, FRCPC, FACNM
Xofigo® (Radium - 223 dichloride) injection is used to treat prostate cancer that is resistant to medical or surgical treatments that lower testosterone. The lesions have spread to the bones with symptoms, but not to other parts of the body such as soft tissues. The condition is termed metastatic castration-resistant prostate cancer or mCRPC. Radium- 223 dichloride is alpha emitter particle with a T ½ life: 11.4 days. It extends the life expectancy of patients to about 30% as compared to a placebo. Common side effects include: nausea, diarrhea, vomiting, peripheral edema, and low blood counts. The administered dose is 1.35uCi per Kilogram Body weight. Read more...

Treatment of Metastatic Bone Pain in Prostate Cancer
Simin Dadparvar, MD, FACNM, FACR
Bone metastasis is a major complication of prostate cancer associated with bone pain. The pain is often dull or aching, worse at nights, and improves with physical activity. Later on, it progresses from low level to chronic pain.
Management of bone pain includes analgesia, radiation, radiofrequency ablation (RF), hormones, chemotherapy, and surgery. Localized pain can be treated with surgery, RF ablation, or external beam radiation. Diffuse pain is treated by analgesics, hormones, chemotherapy, or radiopharmaceuticals. Read more...

Top 10 interesting articles on Prostate cancer
Saabry Osmany, MD

Answer to November 2015 Case of the Month
HISTORY: A 60-year-old male with moderate risk factors for cardiovascular disease and an incident of chest pain presents for myocardial perfusion imaging in your Nuclear Medicine department.  What is the most likely cause of the findings in the inferolateral wall? Please click here for entire case.

ANSWER:  The axes are not properly aligned/not matched between stress and rest MPS slices (dashed yellow lines) causing false positive finding for ischemia in the inferolateral wall.  After correction (images not displayed here), the study appeared normal.

January 2016 Case of the Month
A 75-year-old gentleman has a history of prostate cancer and rising PSA levels. Please click here for images.

Editors and Contributors:
Editor in Chief: Simin Dadparvar, MD
Associate Editor: Twyla Bartel, DO, MBA

Co-Editors:
Gholam R. Berenji, MD
Manohar Kuruva, MD
Yuxin Li, MD, PhD
Pareen Mehta, MD
Chiayi Ni, MD
Saabry Osmany, MD
Jian Q. Yu, MD